
|Videos|June 2, 2022
Treatment Approaches for Good Risk Patients with Renal Cell Carcinoma
Author(s)Tom Powles, MBBS, MRCP, MD, Brian Shimkus, MD
A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
3
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
4
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
5





























































